All publications

Export 28 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Female  [Clear All Filters]
2018
Ragonnet-Cronin M, Hué S, Hodcroft EB, Tostevin A, Dunn D, Fawcett T, Pozniak A, Brown AE, Delpech V, Brown AJLeigh.  2018.  Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance data.. Lancet HIV. 5(6):e309-e316.
2015
Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane P A.  2015.  Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom. Clin Infect Dis. 61:829-36.
2014
Hodcroft E, Hadfield J, Fearnhill E, Phillips AN, Dunn DT, O’Shea S, Pillay D, Leigh Brown A.  2014.  The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10:e1004112.
Bulteel N, Bansi-Matharu L., Churchill D, Dunn DT, Bibby D., Hill T, Sabin CA, Nelson M.  2014.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.
UK HIV Drug Resistance Database.  2014.  The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.
Hue S, Brown A, Ragonnet-Cronin M, Lycett S, Dunn DT, Fearnhill E, Dolling D, Pozniak A, Pillay D, Delpech V et al..  2014.  Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. AIDS. 28:1967-75.
2013
De Luca A., Dunn DT, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
Santoro MM, Sabin CA, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Mackie N, Dunn DT, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin CA, Geretti AM.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
Dolling D, Dunn DT, Sutherland K.A, Pillay D, Mbisa JL, Parry C.M, Post FA, Sabin CA, Cane P A.  2013.  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips AN, Dunn DT.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Waters L., Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn DT, Phillips AN.  2013.  Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.
2012
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn DT.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A, Churchill D, Williams I, Geretti AM et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.
2011
Prosperi M.C, Mackie N, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
Wittkop L., Günthard HF, de Wolf F., Dunn DT, Cozzi-Lepri A, De Luca A., Kucherer C., Obel N., von Wyl V., Masquelier B. et al..  2011.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71.
Bansi L, Smith C, Phillips AN, Kirk S., Geretti AM, Johnson M, Mackie N, Post FA, Gazzard B, Dunn DT et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
2010
Mackie N, Phillips AN, Kaye S, Booth C, Geretti AM.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
Harrison LJ, Castro H, Cane P A, Pillay D, Booth C, Phillips AN, Geretti AM, Dunn DT.  2010.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 24:1917-22.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B., Pillay D, Dunn DT.  2010.  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.